Your browser doesn't support javascript.
loading
The Gut Microbiota and Diabetes: Research, Translation, and Clinical Applications-2023 Diabetes, Diabetes Care, and Diabetologia Expert Forum.
Byndloss, Mariana; Devkota, Suzanne; Duca, Frank; Niess, Jan Hendrik; Nieuwdorp, Max; Orho-Melander, Marju; Sanz, Yolanda; Tremaroli, Valentina; Zhao, Liping.
Afiliación
  • Byndloss M; Vanderbilt University Medical Center, Nashville, TN.
  • Devkota S; Howard Hughes Medical Institute, Vanderbilt University Medical Center, Nashville, TN.
  • Duca F; Human Microbiome Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
  • Niess JH; University of Arizona, Tucson, AZ.
  • Nieuwdorp M; Department of Biomedicine, University of Basel, Basel, Switzerland.
  • Orho-Melander M; Department of Gastroenterology and Hepatology, University Digestive Healthcare Center, Clarunis, Basel, Switzerland.
  • Sanz Y; Department of Internal and Vascular Medicine, Amsterdam University Medical Centers, Amsterdam, the Netherlands.
  • Tremaroli V; Amsterdam Diabeter Center, Amsterdam University Medical Centers, Amsterdam, the Netherlands.
  • Zhao L; Department of Clinical Sciences in Malmö, Lund University Diabetes Centre, Lund University, Malmö, Sweden.
Diabetes ; 73(9): 1391-1410, 2024 Sep 01.
Article en En | MEDLINE | ID: mdl-38912690
ABSTRACT
This article summarizes the state of the science on the role of the gut microbiota (GM) in diabetes from a recent international expert forum organized by Diabetes, Diabetes Care, and Diabetologia, which was held at the European Association for the Study of Diabetes 2023 Annual Meeting in Hamburg, Germany. Forum participants included clinicians and basic scientists who are leading investigators in the field of the intestinal microbiome and metabolism. Their conclusions were as follows 1) the GM may be involved in the pathophysiology of type 2 diabetes, as microbially produced metabolites associate both positively and negatively with the disease, and mechanistic links of GM functions (e.g., genes for butyrate production) with glucose metabolism have recently emerged through the use of Mendelian randomization in humans; 2) the highly individualized nature of the GM poses a major research obstacle, and large cohorts and a deep-sequencing metagenomic approach are required for robust assessments of associations and causation; 3) because single-time point sampling misses intraindividual GM dynamics, future studies with repeated measures within individuals are needed; and 4) much future research will be required to determine the applicability of this expanding knowledge to diabetes diagnosis and treatment, and novel technologies and improved computational tools will be important to achieve this goal.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Microbioma Gastrointestinal Límite: Humans Idioma: En Revista: Diabetes Año: 2024 Tipo del documento: Article País de afiliación: Túnez Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Microbioma Gastrointestinal Límite: Humans Idioma: En Revista: Diabetes Año: 2024 Tipo del documento: Article País de afiliación: Túnez Pais de publicación: Estados Unidos